Recruitment for the dosimetry phase of Clarity’s Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed
Sydney, Australia 10 November 2021 Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dosimetry data is being prepared for Safety Review Committee before moving into therapeutic applications with 67Cu SAR-bisPSMA therapy. Clarity shares…